Table 1.
Summary of results of completed tyrosine kinase inhibitor trials.
| Tyrosine Kinase Inhibitors | Target(s) | Mutations | ORR | mPFS (months) | mOS (months) | Clinical Trial ID |
|---|---|---|---|---|---|---|
| Vandetanib ( 22 ) | VEGFR2-3, EGFR, RET | RET+RAS+UK | 45% | 30.5 | NR | NCT00410761 |
| Cabozantinib ( 23 ) | VEGFR2, KIT, FLT-3, RET, MET | RET+RAS+UK | 28% | 11.2 | 26.6 | NCT00704730 |
| M918T Negative | 20% | 20.2 | 5.7 | |||
| M918T | 34% | 13.9 | 44.3 | |||
| Selpercatinib ( 24 ) | RET, VEGFR2 | RET/Previous TKI | 69% | NR (1-year PFS 82%) | NR | NCT03157128 |
| RET/TKI Naïve | 73% | NR (1-year PFS 92%) | NR | |||
| Sorafenib ( 25 ) | BRAF, KIT, FLT-3, VEGFR2, PDGFR | ND | 25% | NR | NR | NCT02114658 |
| Lenvatinib ( 26 ) | VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET | RET+RAS | 36% | 9 | 16.6 | NCT00784303 |
| Anlotinib ( 27 ) | VEGFR1-3, FGFR1-4, KIT FGFR | ND | 48.4% | 22.4 | 50.4 | NCT02586350 |
| Pralsetinib ( 28 ) | RET, VEGFR2 | RET/Previous TKI | 60% | NR | NR | NCT03037385 |
| RET/TKI Naïve | 71% | NR | NR | |||
| Sunitinib ( 29 ) | PDGFR, KIT VEGFR1-3, FLT-3, RET | ND | 38.5% | 16.5 | 29.4 | NCT00510640 |
Completed trials with corresponding references are included. Mutation status is indicated as RET altered (RET), RAS altered (RAS), unknown (UK), and not determine (ND). Objective response rate (ORR), Progression free survival (PFS), and overall survival (OS) are indicated. NR indicates that median PFS or OS have not been reached.